Integumen PLC Issue of Equity: Shares in Lieu of Invoice (1674P)

TIDMSKIN

RNS Number : 1674P

Integumen PLC

08 October 2019

AIM share code: SKIN

8 October 2019

Integumen PLC

("Integumen" or "Company")

Issue of Equity : Shares in Lieu of Invoice

Integumen announces that it has been requested to issue 1,176,471 ordinary shares of 0.01p in the share capital of Integumen in exchange for amounts due under an invoice from one of the Company's service providers dated 16 September 2019 ("the Invoice Shares"). The consideration for the Invoice Shares amounts, in aggregate, to a cash value of GBP20,000.

At a board meeting held today, 1,176,471 shares have been allotted. Application has today been for these shares to be admitted to trading on AIM, and such Admission is expected on or around 14 October 2019.

Total voting rights

The Company's total issued share capital, following the issue of the Invoice Shares, will be 981,163,373 ordinary shares. As the Company does not hold any shares in Treasury, this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company following Admission.

 
 Integumen plc              Gerard Brandon, CEO    [phone] 
 SPARK Advisory Partners 
  Limited 
  (Nominated Adviser)       Neil Baldwin           [phone] 
                           ---------------------  --------------------- 
 Turner Pope Investments    Andy Thacker/Zoe 
  (TPI) Limited (Broker)     Alexander             [phone] 
                           ---------------------  --------------------- 
 

About Integumen:

Integumen is a vertically integrated product and services company for skin related diseases, treatments and therapies with three business units:

-- Labskin AI's technology platform incorporates artificial intelligence within clinical research for medical device, pharmaceuticals, cosmeceuticals and related life science test services. Labskin allows skincare, healthcare, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.

-- Wound pHase is developing skin and wound care products using its proprietary wound dressing technology. Working in collaboration with CBD providers creating a CBD infused diabetic wound care product range.

Stoer-for-men skin products e-commerce division offers a range of skincare products derived from 5 natural super-ingredient plant extracts specifically for men to reduce the signs of ageing and is also used as a control for client testing within Labskin laboratories.

The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

IOEBBBDGBXGBGCI

(END) Dow Jones Newswires

October 08, 2019 07:34 ET (11:34 GMT)